Buy Buy Buy: 6 one-of-a-kind ASX growth stocks

All buys, no holds, no sells. Claudia Kwan of NorthStar and Jun Bei Liu of Ten Cap pitch 6 ASX companies that are in a league of their own.
Anna Dadic

Livewire Markets

Singular. Unique. One of a kind. Rare. A true original. In a world driven by the attention economy, words like these can quickly lose their currency.

The same goes for the market. Momentum regularly shifts the spotlight onto whatever the hottest trend of the moment happens to be, making it harder to spot businesses with a genuine, lasting edge.

That’s why in this episode of Buy Hold Sell, we wanted to focus on real growth and true innovators, no matter where they sit on the market spectrum. 

We asked our two guests, Claudia Kwan of NorthStar Impact Funds and Jun Bei Liu of Ten Cap, who each operate in different corners of the market, to pitch the growth stocks they believe fit this brief: businesses that are doing something genuinely different and stand apart from the pack. 

 

This episode was filmed Tuesday 17th November 2026.

Other ways to listen 

Edited transcript

Anna Dadic: Hello, and welcome to Livewire's Buy Hold Sell. I'm your host, Anna Dadic. In this episode, we're asking the question: what separates a good growth stock from a true category-of-one company? 

Today, we're hunting for true growth - companies on the ASX doing something genuinely different - and unpacking why nobody else can replicate them. 

It's an all-buys special: three stocks each, zero holds, and zero sells. I'm joined by Jun Bei Liu from Ten Cap and Claudia Kwan from North Star Impact Funds, two managers fishing in completely different ponds across the ASX, from global category leaders to emerging disruptors. Let's see what they're coming to the table with. 

Claudia, I'm going to start with you. Can you please name your first stock, why it's a buy, and what makes it genuinely innovative or different?

1. Janus Electric Holdings (ASX: JNS) 

Claudia Kwan: The stock is called Janus Electric, ticker JNS. It's a buy because I think these small-cap companies are really thriving on multiple catalysts. This is a swappable battery company for heavy-duty trucks, which is a very hard-to-abate sector. 

The company has 124 trucks in the order book, and they have a capacity of 600 trucks per annum. So for the company to deliver on those, there is a lot of upside, and the addressable market for heavy-duty trucks is huge. Their market at the moment is actually the US. 

And if you look at the economics for truck drivers, you can use this heavy-duty swappable battery solution from Janus for $150,000 versus buying an EV truck for $500,000. We also know that the US has banned Chinese EVs, but they also have regulation around different areas. So there's a port in California where they are required to be electric by 2035. 

So Janus has a very, very large pond to fish from. And in terms of demand, they can move from California across states in the US where regulation is supportive. And you also have Australia as well.



2. Life 360 (ASX: 360) 

Anna Dadic: Jun Bei, let's start with a completely different type of network. What's your first stock, why is it a buy, and why can't competitors replicate it?

Jun Bei Liu: So this stock I've been talking about for years, so it's Life360 - still my favourite. What's special about this business is that this company essentially invented, or was first to really create, the tracking society, really. And that's even before Apple launched its Find My iPhone and the like. 

So when Find My iPhone was first launched, everyone said it marked the end of Life360 and the like, but literally they realised that what it did is really just expand the market. And that whole tracking society, or tracking circle, has been growing ever since around the world and for multiple different categories, which I'll go into. It's interesting that when I was young, I didn't like to be tracked, but now I look at how I track my kids and they actually... It's fantastic. I track everything. I track my suitcase, I track my kids, track my pets, track my car. Everything that can go missing. 

But what the young people use trackers for is that they actually see it as their way of staying in touch. They look at their friends, they pull it up and go, "Oh, all my friends are here. They haven't left their house for three days." So this is how they use it. And it's actually probably one of the top five most-used social media apps in the US - and this is comparing it with Facebook and the like. So incredible strength within this community. 

Since the pure tracking app, it has launched into pets and others, and also started having an insurance product, and then more recently it started selling advertising spots as well, which is doing incredibly well. The company's gone through challenges, as all these SaaS businesses have, but since then the business actually has been proving strength to strength. The growth is still very strong, and the ad revenue is growing stronger as well.

So growing at 40% - it's very rare to find something on the ASX growing that fast. And there are many years, multiple years to come in terms of growth. So that is my pick, and I think it will do very well for investors.

Anna Dadic: I didn't actually realise it predated Find My iPhone.

Jun Bei Liu: So when Apple came through, everyone said that's the end of it; it's not going to go anywhere. But all of this just expanded it, because you know why? Because Apple and Google and others, when they launch those products, they don't want to go and be a disruptor for that category. All they want is to keep the user within their own ecosystem. 

So they're not going to have a product that can be used on Google and others. Whereas Life360, essentially, their goal is to let people be able to track, whereas the others are different. So it's a fascinating space. And the company, in fact, over the last 10 years has received multiple approaches from those large tech businesses to buy it. But look, the company said no because they see a lot more growth to come.



3. Chrysos Corporation (ASX: C79) 

Anna Dadic: Claudia, you're up with stock number two. What is it, and how is it rewriting the rules?

Claudia Kwan: So this company is called Chrysos. The ticker is C79. It's a part of the fundamental, long-term structural area I want to be part of, which is industrial resiliency and sustainable resource extraction. 

The Chrysos technology came out of the CSIRO, and it is a disruptor. It's photon assay, and it's disrupting fire assay. So essentially what it does is it's a very low-chemical solution for miners, and they've targeted gold miners specifically in this first instance to assess what the sample is. And if you look at their customer base already, they already have half of the world's largest gold miners, and they have all the testing labs - so Intertek, Bureau Veritas, et cetera. So it's proven the technology is a disruptor. They have 46 units of an addressable market of 600 units. And the business model and the economics are phenomenal because they get a subscription and they also get a pay-per-use.

So when gold was rallying a lot, they're using a lot more. That is pure bottom line—that goes straight to the bottom line. So the share price currently is factoring in 10 units versus management's guidance of 15 units per year. The company has struggled to probably sometimes meet the units, but what we saw in the last results was that assay sample revenue really coming in there. 

So the operating leverage on this business is phenomenal, and it doesn't just stop at gold—then you can go to other commodities. So what do we like? We like that it's a genuine disruptor. We like that the technology is very, very sophisticated and hard to disrupt. We like that the addressable market is very large. And what we know to be true is that we're structurally positive on gold and also other commodities. So really what we're looking for in this upcoming result is the number of units that the company's been able to deploy.

Anna Dadic: Okay. And they're intentionally starting with gold before moving on to other commodities?

Claudia Kwan: Yeah, absolutely. I mean, as you can see by the 46 units versus the addressable market, they don't even need to have another commodity, in fact. And for traditional users, they're going to have negative free cash flow for some time, because actually the more negative the free cash flow, the more growth they have. But when you look at the economics on these businesses, it's very, very hard to find something with such strong operating leverage that's correlated to all the structural long-term growth places to be, and is highly undisruptible.


 


4. Cuscal (ASX: CCL) 

Anna Dadic: Jun Bei, let's look at another company owning critical behind-the-scenes infrastructure. If you could name your second pick, and what's their unfair advantage?

Jun Bei Liu: Well, you're already giving a hint, so you should have a guess what it is. So the company is Cuscal. The code is CCL - the old Coca-Cola code. This company is exactly like you said: it provides digital infrastructure for essentially the backend for digital payments to take place. It is the largest outside the big four banks. 

In fact, when this company was formed, it was essentially formed by a group of credit unions and smaller regional banks as a joint venture. And some of those banks remain to be the larger shareholders within the business. 

Only listed a few years ago, share price has done incredibly well. And just think about it: every time you do a digital payment tap, this company gets a clip. So it's leveraged to the volume, not so much the pricing. And the business has been doing really well, growing in the 20s.

The company just gave guidance for another 20% - over 20% - growth. And now it's moving into different markets as well, into New Zealand more recently with an acquisition. And then the whole landscape where it operates in is actually still quite fragmented; even though it's the largest, there's still a lot of opportunity for them to have those bolt-on acquisitions, and they're incredibly accretive. Just since listing, I think the company has made a couple of acquisitions and they've been very, very accretive to earnings. 

So yeah, I continue to see this company continue to grow. It's still a smallish company, so we'd love to be positioned in the smaller company as they grow into the index, and you attract more new investors and more coverage, more people understanding the business. So we think this one is still at its early stage of growth, and gradually moving into different indexes over the next few years, we'll see this gaining much more traction.

Anna Dadic: I don't see tapping winding back anytime soon.

Jun Bei Liu: I haven't seen cash for a while.


 
5. TechnologyOne (ASX: TNE)

Anna Dadic: So for our final round, let's look at two businesses that have built true category-of-one dominance on the global stage. Claudia, what's your pick?

Claudia Kwan: TechnologyOne. I mean, it's not on the global stage - it has the UK as well as Australia - but when we look at AI and all the opportunities that you have, Australia obviously is limited in being able to access the Anthropics and the NVIDIAs of the world and the semiconductors. 

However, what we are really looking for in 2027 is earnings resilience. I think companies with predictable earnings—they actually really don't have to do much, and valuations are actually quite compelling for that. And also companies that we like with leverage to AI are actually those that really get the AI margin uplift that's actually quite predictable. So TechnologyOne, as we walk through, actually has genuine use cases of ROI for their customers from AI, which is really hard to say at this moment in time when the debate really is around how much AI corporates can consume. Uber ran out very quickly, whereas Kogan was in the AFR saying they have unlimited access for their staff.

But that debate really isn't even a debate for TechnologyOne because of their customers, which are councils and universities. Their customer base actually now extends from not just councils, but ratepayers, and then from universities to the students. And actually, you use much less AI when you have very clean data and a defined data set. So if I'm going on and I'm looking all over the web for whether or not I, as a student, can take a course at Sydney University, I'm using a lot more tokens or a lot more AI power. But if I'm using TechnologyOne Plus embedded in a university and I'm online saying, "This is what I've done, am I eligible for this course, and what's the timetabling?" I'm using much less data. But for TechnologyOne, they don't have the huge CapEx associated like the Anthropics or the data centres or the neoclouds, yet they start to actually get in a new user, and their revenue is actually leveraged to usage as well.

So I think it's just a much cleaner, easier way to play AI with companies that don't have these circular financing, complex debt structures, plus huge CapEx bills with sort of unknown use cases of ROI. So there are multiple councils that have actually said they've used TechnologyOne Plus and it's allowed them to approve the amount of bridges or infrastructure they normally do in a year in six months. That's like a reportable ROI for that council. And so as long as you get this clear moat and clear ROI, TechnologyOne can charge for that. So what you're getting now is a very, very well-built company with a new customer base and new revenue base, and that's only just at the beginning. So these are the companies which I think have a really long way to go, and I think that they have really, really strong shareholder support because of the predictability around the earnings.


 


6. Pro Medicus (ASX: PME) 

Anna Dadic: Jun Bei, close us out. What's your pick?

Jun Bei Liu: So my pick is Pro Medicus. We've followed this company since it was a tiny baby company, now grown into a large business.

Anna Dadic: I think you're known as a staunch supporter!

Jun Bei Liu: Yeah, that's right. Yes, always in it. So what's amazing about this business is essentially it identifies a problem within the healthcare space. So the healthcare industry is probably one of the last industries to digitise. And that's why more recently, a lot of the new technology tools, AI tools and things, are all happening within the healthcare space—because it's so manual, so many people and manual processes that are involved, and it's open to be disrupted. 

Now, this company many years ago came up with this very innovative way of packaging its imaging. So for radiology, for radiologists, you go and take a scan, and then you have to take it to the radiologist to read it, and they'll charge you lots of money, and they charge the government lots of money, and then they'll have their interpretation and the like. But then every time that image needs to be taken to the next specialist, you've got to physically move them and take them to different places.

So the company has come up with this novel tool. They essentially repackage it, and then you can just send it straight away with very high resolution in real time. And over the years, it's been done and tested, penetrated fully in the Australian market, and went to the US. That was many years ago now. As soon as they went to the US, very quickly they signed up the top hospitals. And ever since then, they've just been adding more and more hospitals. 

And what's also amazing about their business model is that a lot of the time with medtech and these businesses, the business model isn't there until they work it out later. But this company—instead of charging per seat, because for me, per seat in the future in the AI world might be a little bit blurry, because do you use AI to read it or do you use the person to read it?

Is it per seat or is it per all that? So they actually charge per volume. So it's linked completely to the volume. So the more images you look at, the more volume that is linked to the process. So ever since they got into one hospital, the volume just keeps growing and growing and growing. And remember, this is like Netflix: the minute you start using it, you want more of it.

Anna Dadic: You can't live without it.

Jun Bei Liu: Exactly. The amount of MRI and all the imaging that's been growing is just phenomenal. And more and more, because we have better technology, better image resolution, now we want more so we can prevent—it's actually going into preventative health as well, just to see if there's any issues and the like. And also what's incredible is that their software has actually been used in a lot of AI training models as well, just because it's so sophisticated and the like. So the business is doing really well, and they've gone to the US and are now growing that. And now they realise, well, they don't just have to stay in one—they're expanding into other categories. You can go into the heart, you can go into other areas, because ultimately you may not look at that many images, but each image will be very high value to see.

So look, lots of growth opportunity. And because this company has been one of the first in innovation and growing in that space, it is actually now very cash-generative and putting that money into some of the early-stage AI imaging-reading businesses, and more recently had an agreement with a couple of listed businesses here in Australia already in different categories. So it just opens up future opportunities. 

I think this is a one-and-only growth company that has really sustained visibility of that growth trajectory. All the hospitals it's gone into, its retention rate is almost 100%, and once it goes in, it grows. The hospital is something a little bit like TNE—it takes 10 years to convert those clients, but once they start using you, it's very difficult to really move the mouse, only to be threatened by others. 

So it's a fascinating business. I think it's something always to have in the portfolio.



Anna Dadic: Six category-of-one businesses across the ASX. Jun Bei Liu and Claudia Kwan, thank you both for bringing your high-conviction buys. Make sure you catch episode two - Jun Bei and Claudia will be back to reveal the stocks they're trimming, exiting, and rotating into next. Thanks for watching Buy Hold Sell.
........
Livewire gives readers access to information and educational content provided by financial services professionals and companies ("Livewire Contributors"). Livewire does not operate under an Australian financial services licence and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any advice given. Any advice on this site is general in nature and does not take into consideration your objectives, financial situation or needs. Before making a decision please consider these and any relevant Product Disclosure Statement. Livewire has commercial relationships with some Livewire Contributors.

6 stocks mentioned

3 contributors mentioned

Anna Dadic
Investment Writer & Presenter
Livewire Markets

I'm an Investment Writer and Presenter at Livewire Markets, dedicated to creating content that makes the world of investing more accessible. With a background in story development, I enjoy distilling complex topics into engaging, impactful media...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment